The plot suggests that high Ki-67 is associated with a better response towards pCR, with most studies reporting that patients who achieve pCR tend to have higher pretherapeutic Ki-67 levels. This reinforces the idea that Ki-67 could serve as a valuable predictive marker for response to NAC in breast cancer patients. The findings suggest that higher Ki-67 levels may predict a favorable response to NAC in breast cancer patients, as evidenced by the association between elevated Ki-67 and pCR. The gene discussed is MKI67; the disease is breast carcinoma.